IBIO Archives - Page 3 of 8

Developments

iBio to present poster highlighting better glycosylation for antibodies produced in plants via its FastPharming System

iBio (NYSE American:IBIO) senior product manager, Rachel Jordan, Ph.D., will present a poster at the annual Protein & Antibody Engineering Summit conference in Boston this week titled, “Plant-Made Antibodies...

May 2, 2022

Developments

iBio advancing vaccine program for multi-variant COVID-19 disease

iBio (NYSE American:IBIO) updated progress on its lead COVID-19 vaccine program, IBIO-202, including a recently received the FDA response to its pre-IND package for IBIO-202. In light of the feedback received, the...

January 26, 2022

Markets

JMP starts iBio at market outperform; PT $1.50

JMP Securities initiated coverage of iBio (NYSE American:IBIO) with a “market outperform” rating and price target of $1.50. The stock closed at 85 cents, up 19 cents, or 29%, on Nov. 29. iBio is a technology...

November 29, 2021

Developments

Omicron variant underscores need for new COVID vaccine candidates like IBIO-202

iBio (NYSE American:IBIO) provided an updated on its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron variant of SARS-CoV-2. According to the WHO, the Omicron variant has at...

November 29, 2021

Developments

iBio, UT Southwestern to investigate IBIO-100 in solid tumors

iBio (NYSEA:IBIO) and the University of Texas Southwestern Medical Center entered into a research collaboration to explore in solid tumors the anti-cancer potential of the molecule that is part of the IBIO-100 program...

November 15, 2021

Developments

iBio acquires FastPharming manufacturing facility

iBio (NYSEA:IBIO) purchased the manufacturing facility it previously operated under a lease from two affiliates of Eastern Capital and also acquired the approximate 30% equity interest in iBio CDMO held by the...

November 4, 2021

Executive Moves

iBio names biotech veteran Chip Clark to the board

William (Chip) Clark iBio (NYSE:IBIO) appointed William (Chip) Clark to the board, effective immediately. Mr. Clark has more than 30 years of biotechnology and pharmaceutical experience, with a focus on business...

August 26, 2021

Developments

iBio acquires exclusive rights to develop anti-CD25 antibody RTX-003 from RubrYc

iBio (NYSEA:IBIO) bolstered its immuno-oncology pipeline with the acquisition of exclusive rights to develop and commercialize the anti-CD25 monoclonal antibody, RTX-003, from RubrYc. The partnership also includes an...

August 25, 2021

Developments

iBio featured in Genetic Engineering & Biotechnology News

The advantages of iBio’s (NYSE American:IBIO) plant-based drug production system was featured in the Aug. 4 edition of Genetic Engineering & Biotechnology News. The article quoted Randy Maddux, COO of iBio, who...

August 5, 2021

Developments

iBio posts positive preclinical immunization studies with next gen COVID-19 vaccine candidate

iBio (NYSE American:IBIO) announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid (N) protein of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T...

July 16, 2021

Tag - IBIO

iBio to present poster highlighting better glycosylation for antibodies produced in plants via its FastPharming System

iBio advancing vaccine program for multi-variant COVID-19 disease

JMP starts iBio at market outperform; PT $1.50

Omicron variant underscores need for new COVID vaccine candidates like IBIO-202

iBio, UT Southwestern to investigate IBIO-100 in solid tumors

iBio acquires FastPharming manufacturing facility

iBio names biotech veteran Chip Clark to the board

iBio acquires exclusive rights to develop anti-CD25 antibody RTX-003 from RubrYc

iBio featured in Genetic Engineering & Biotechnology News

iBio posts positive preclinical immunization studies with next gen COVID-19 vaccine candidate

General

More